MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
MaxCyte, Inc.NASDAQ: MXCT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 15.4% from a year ago
Total assets stood at $194.47M at the end of Q1 FY2026, down 15.4% from a year earlier and down 4.0% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Total assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -15.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 202.51M USD
- Year-over-year change
- -15.4%
- 4-year CAGR
- -8.1%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 202.51M | -15.4% |
| FY2024 | 2024-12-31 | 239.47M | -10.7% |
| FY2023 | 2023-12-31 | 268.27M | -6.4% |
| FY2022 | 2022-12-31 | 286.65M | +0.9% |
| FY2021 | 2021-12-31 | 284.12M | — |
Total Assets vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's Mar 2026 total assets of $194.47M is the 3rd highest of the 11 companies compared; the peer median is $80.23M.
- Its year-over-year change of -15.4% is the 8th highest of 11, against a peer median of +5.9%.
- Over three fiscal years its annual growth of -10.9% compares with a peer median of +10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $410.77M | +24.7% | +66.3% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $294.72M | +401.3% | +12.9% |
| Mar 2026 | $194.47M | -15.4% | -10.9% | |
| Mar 2026 | $175.3M | -14.1% | -13.3% | |
| Dec 2025 | $162.17M | -22.8% | -13.9% | |
| Mar 2026 | $86.76M | +68.8% | +13.8% | |
| Mar 2026 | $73.7M | +21.1% | +44.1% | |
| Mar 2026 | $70.98M | +148.0% | +17.1% | |
| Mar 2026 | $69.8M | -20.0% | -10.7% | |
| Mar 2026 | $66.22M | -9.2% | +8.6% | |
| Mar 2026 | $59.97M | -30.4% | -52.6% | |
| Peer median (excluding MXCT) | $80.23M | +5.9% | +10.7% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 47.78M | 11.07M | 46.51M | 27.88M | 20.07M |
| Short-term Investments | 207.26M | 216.28M | 121.78M | 126.6M | 82.98M |
| Net Receivables | 6.88M | 11.18M | 5.78M | 4.68M | 3.5M |
| Inventory | 5.2M | 8.58M | 12.23M | 8.91M | 7.55M |
| Other Current Assets | 0 | 1.91M | 3.9M | 3.61M | 4.28M |
| Total Current Assets | 270.43M | 252.27M | 190.19M | 171.68M | 118.37M |
| Property, Plant & Equipment (Net) | 13.37M | 33.58M | 34.75M | 30.47M | 28.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 650K |
| Long-term Investments | 0 | 0 | 42.94M | 35.78M | 52.57M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 316.7K | 809K | 388K | 1.53M | 2.47M |
| Total Non-current Assets | 13.69M | 34.39M | 78.08M | 67.79M | 84.14M |
| Total Assets | 284.12M | 286.65M | 268.27M | 239.47M | 202.51M |
| Account Payables | 1.82M | 292K | 743K | 1.36M | 1.4M |
| Short-term Debt | 0 | 0 | 0 | 864K | 1.46M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.75M | 0 | 5.07M | 5.25M | 3.6M |
| Other Current Liabilities | 0 | 6.71M | 0 | 8.3M | 7.81M |
| Total Current Liabilities | 15.62M | 15.43M | 17.86M | 15.78M | 14.27M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 450.2K | 1.32M | 283K | 274K | 263K |
| Total Non-current Liabilities | 5.61M | 17.26M | 18.25M | 17.44M | 16.75M |
| Total Liabilities | 21.22M | 32.69M | 36.11M | 33.22M | 31.02M |
| Common Stock | 1.01M | 1.02M | 1.04M | 1.06M | 1.07M |
| Retained Earnings | (114.3M) | (137.88M) | (175.8M) | (216.85M) | (261.48M) |
| Accumulated OCI | 0 | (0) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 262.9M | 253.97M | 232.17M | 206.25M | 171.49M |
| Total Debt | 5.68M | 16.1M | 18.74M | 18.03M | 17.94M |
| Net Debt | (42.1M) | 5.03M | (27.76M) | (9.85M) | (2.12M) |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.